Document Detail


Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
MedLine Citation:
PMID:  12553629     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
During the past several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. The first article of this 2-part update reviewed the tumor necrosis factor (TNF) inhibitors, infliximab and etanercept. In this article, we will review 2 therapies that target the T cell, efalizumab and alefacept.
Authors:
Jeffrey M Weinberg; William D Tutrone
Related Documents :
2535129 - Humoral immunopathological mechanisms in the skin.
9531159 - Role of t cells in atopic dermatitis. new aspects on the dynamics of cytokine productio...
1390169 - Topical vitamin c protects porcine skin from ultraviolet radiation-induced damage.
11182289 - Redox-modulated pathways in inflammatory skin diseases.
16936899 - Ultraviolet light induced alteration to the skin.
19890059 - The cutaneous biochemical redox barrier: a component of the innate immune defenses agai...
16103989 - Function and therapeutic potential of host defence peptides.
11390439 - Immunoproteasomes shape immunodominance hierarchies of antiviral cd8(+) t cells at the ...
9383829 - Immune aspects of endometriosis: relevance of the uterine mucosal immune system.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cutis     Volume:  71     ISSN:  0011-4162     ISO Abbreviation:  Cutis     Publication Date:  2003 Jan 
Date Detail:
Created Date:  2003-01-29     Completed Date:  2003-04-18     Revised Date:  2013-09-12    
Medline Journal Info:
Nlm Unique ID:  0006440     Medline TA:  Cutis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  41-5     Citation Subset:  IM    
Affiliation:
Department of Dermatology. St. Luke's-Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA. jmw27@columbia.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / administration & dosage*,  pharmacology,  therapeutic use*
Biological Therapy*
Drug Delivery Systems*
Humans
Psoriasis / drug therapy*
Recombinant Fusion Proteins / administration & dosage*,  pharmacology,  therapeutic use*
T-Lymphocytes / drug effects*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Recombinant Fusion Proteins; 0/efalizumab; ELK3V90G6C/alefacept

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Topical therapy with tretinoin and ammonium lactate for acanthosis nigricans associated with obesity...
Next Document:  Chondroid syringoma.